Aging population and higher disease prevalence are driving the hereditary transthyretin amyloidosis market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Hereditary Transthyretin Amyloidosis Market During The Forecast Period?
The market for hereditary transthyretin amyloidosis has experienced strong growth in recent years. It is projected to increase from $1.49 billion in 2025 to $1.62 billion in 2026, at a compound annual growth rate (CAGR) of 9.0%. This growth in the past can be attributed to several factors, including the increasing clinical recognition of attr amyloidosis, the introduction of tafamidis therapy, the expansion of specialized neurology and cardiology centers, advancements in genetic testing for ttr mutations, and the rise of patient registry programs.
The hereditary transthyretin amyloidosis market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $2.28 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.9%. Factors driving this growth during the forecast period include the proliferation of next-generation gene therapies, increased funding for rare disease research, broader implementation of precision medicine strategies, the emergence of CRISPR-based treatments, and advancements in technologies for monitoring disease outcomes. Key trends expected over the forecast horizon encompass a greater uptake of gene silencing therapies, an increase in the application of RNAi-based treatments, a heightened emphasis on prompt cardiac and neurological diagnosis, a wider availability of oral therapeutic alternatives, and improved long-term approaches to disease management.
Access Your Free Sample Report For In-Depth Market Analysis:
What Major Factors Are Driving The Hereditary Transthyretin Amyloidosis Market Forward?
The expanding geriatric population is anticipated to propel the hereditary transthyretin amyloidosis market forward. This demographic encompasses individuals aged 65 and older, frequently necessitating specialized healthcare and support due to the aging process. The growth in the geriatric population is attributed to increasing life expectancy, driven by advancements in healthcare and enhanced living conditions. Hereditary transthyretin amyloidosis (hATTR) profoundly impacts this older age group by inducing progressive neuropathy and cardiomyopathy, which leads to increased morbidity among aging individuals. For instance, in January 2024, data from the US-based nonprofit Population Reference Bureau indicated that the US population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Consequently, the growing geriatric population is a key driver for the expansion of the hereditary transthyretin amyloidosis market.
Which Segments Define The Hereditary Transthyretin Amyloidosis Market Segment Structure?
The hereditary transthyretin amyloidosis market covered in this report is segmented –
1) By Type: Oral, Subcutaneous Injection, Other Types
2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Oral: Tafamidis, Experimental Oral Therapies
2) By Subcutaneous Injection: Inotersen, Vutrisiran
3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies
Which Trends Are Impacting The Progress Of The Hereditary Transthyretin Amyloidosis Market?
Leading companies in the hereditary transthyretin amyloidosis market are actively developing novel therapeutics, such as RNAi treatments, with the goal of targeting and reducing the production of transthyretin (TTR) protein. These RNAi therapeutics constitute a class of medications that leverage RNA interference technology to silence specific genes, thereby diminishing the creation of disease-causing proteins. For instance, in October 2024, Alnylam Pharmaceuticals, Inc., a US-based biopharmaceutical company, submitted a supplemental new drug application (sNDA) to the US FDA for Vutrisiran (AMVUTTRA) as a therapy for transthyretin amyloidosis with cardiomyopathy. This submission emphasizes its innovative RNAi therapeutic approach, specifically designed to target and decrease transthyretin (TTR) protein, which is a crucial factor in the progression of the disease. Vutrisiran’s subcutaneous administration offers a more convenient and patient-friendly dosing regimen compared to traditional intravenous treatments, establishing it as a potentially transformative option for individuals living with this serious condition.
Who Are The Established Players Within The Hereditary Transthyretin Amyloidosis Market?
Major companies operating in the hereditary transthyretin amyloidosis market are Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Pfizer Inc., Eli Lilly and Company, Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb, Merck and Co Inc., Johnson and Johnson, AbbVie Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Amgen Inc.
Get The Full Hereditary Transthyretin Amyloidosis Market Report:
Where Is The Hereditary Transthyretin Amyloidosis Market Most Concentrated Geographically?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Hereditary Transthyretin Amyloidosis Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Hereditary Transthyretin Amyloidosis Market 2026, By The Business Research Company
Alzheimers Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Atrophic Glossitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/atrophic-glossitis-treatment-global-market-report
Progressive Ataxia And Weakness Disorders Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
